secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-05-12T11:05:23+00:00
Accession:  0001628280-26-033861
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q1 2026 net loss $25.1M; cash $268.3M; new Roche DAC collaboration
--------------------------------------------------------------------------------

- Revenue $6.2M (down from $7.2M YoY); net loss $25.1M ($0.20 EPS) vs $26.3M ($0.37 EPS).
- Cash $268.3M at March 31, 2026; runway to end of 2028.
- Decision to not advance CFT8919 (EGFR L858R degrader) outside Greater China.
- New collaboration with Roche for degrader-antibody conjugates; $20M upfront payment received.
- Cemsidomide Phase 2 MOMENTUM trial enrollment on track; Phase 1b with elranatamab first patient dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/0001628280-26-033861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026033861/cccc-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer